Efeitos do cilostazol em rim e musculatura estriada esquelética de ratos Wistar submetidos à isquemia aguda e reperfusão de membros posteriores by Moreira Neto, Antonio Augusto et al.
  Universidade de São Paulo
 
2012
 
Effects of cilostazol in kidney and skeletal
striated muscle of Wistar rats submitted to
acute ischemia and reperfusion of hind limbs
 
 
ACTA CIRURGICA BRASILEIRA, SAO PAULO, v. 27, n. 11, pp. 783-788, NOV, 2012
http://www.producao.usp.br/handle/BDPI/36114
 
Downloaded from: Biblioteca Digital da Produção Intelectual - BDPI, Universidade de São Paulo
Biblioteca Digital da Produção Intelectual - BDPI
Departamento de Patologia - FM/MPT Artigos e Materiais de Revistas Científicas - FM/MPT
Acta Cirúrgica Brasileira - Vol. 27 (11) 2012 - 783
7 - ORIGINAL ARTICLE 
ISCHEMIA/REPERFUSION
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ABSTRACT
PURPOSE: To investigate the effect of cilostazol, in kidney and skeletal muscle of rats submitted to acute ischemia and reperfusion. 
METHODS: Fourty three animals were randomized and divided into two groups. Group I received a solution of cilostazol (10 mg/
Kg) and group II received saline solution 0.9% (SS) by orogastric tube after ligature of the abdominal aorta. After four hours of 
ischemia the animals were divided into four subgroups: group IA (Cilostazol): two hours of reperfusion. Group IIA (SS): two hours 
of reperfusion. Group IB (Cilostazol): six hours of reperfusion. Group IIB (SS) six hours of reperfusion. After reperfusion, a left 
nephrectomy was performed and removal of the muscles of the hind limb. The histological parameters were studied. In kidney cylinders 
of myoglobin, vacuolar degeneration and acute tubular necrosis. In muscle interstitial edema, inflammatory infiltrate, hypereosinophilia 
fiber, cariopicnose and necrosis. Apoptosis was assessed by immunohistochemistry for cleaved caspase-3 and TUNEL. 
RESULTS: There was no statistically significant difference between groups. 
CONCLUSION: Cilostazol had no protective effect on the kidney and the skeletal striated muscle in rats submitted to acute ischemia 
and reperfusion in this model.
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RESUMO
OBJETIVO: Investigar o efeito do cilostazol no rim e na musculatura esquelética de ratos submetidos à isquemia aguda e reperfusão. 
MÉTODOS: Quarenta e três animais foram aleatoriamente distribuídos em dois grupos. Grupo I recebeu solução de cilostazol (10 
mg/Kg) e Grupo II recebeu solução fisiológica a 0,9% (SF), após ligadura da aorta abdominal. Decorridas quatro horas de isquemia 
os animais foram distribuídos em quatro subgrupos: Grupo IA (Cilostazol): duas horas de reperfusão. Grupo IIA (SF): duas horas de 
reperfusão. Grupo IB (Cilostazol): seis horas de reperfusão. Grupo IIB (SF): seis horas de reperfusão. Após a reperfusão, realizou-se 
nefrectomia esquerda e a retirada da musculatura de membro posterior. Os parâmetros histológicos estudados em rim foram cilindros 
de mioglobina, degeneração vacuolar e necrose tubular. Em músculo foram edema, infiltrado inflamatório, hipereosinofilia de fibras, 
cariopicnose e necrose. A apoptose foi avaliada por imunohistoquímica, através da caspase-3 clivada e TUNEL. 
RESULTADOS: Não houve diferença estatisticamente significante entre os grupos estudados. 
CONCLUSÃO: O cilostazol não teve efeito protetor sobre o rim e sobre a musculatura estriada esquelética em ratos Wistar submetidos 
à isquemia aguda e reperfusão no modelo estudado. 
Descritores: Isquemia. Reperfusão. Imunoistoquímica. Histologia. Ratos.
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Introduction
The reperfusion syndrome is characterized by 
metabolic acidosis, hyperkalemia by the loss of intracellular 
potassium, increased serum creatine kinase and myoglobin with 
myoglobinury1. May result in acute renal failure: coagulation 
disorders, accumulation of extracellular fluid and acute pulmonary 
distress2.
With the acute ischemia, initiating anaerobic metabolism, 
glycogen with transformation into lactate, leading to decreased 
production of adenosine triphosphate (ATP), which alters the 
permeability of the cell muscle, allowing the output of potassium 
and myoglobin and entry Sodium and calcium célula3.
The cell damage occurs only after an interval of thirty 
minutes of ischemia and irreversible changes in skeletal muscle 
occur after four to six hours of ischemia. Ischemia can lead to cell 
death by necrosis or apoptosis4.
The caspases are a group of protease essential for 
apoptosis, which makes irreversible cleavage of DNA. The 
cascade activation of caspases can be triggered by many factors, 
such as the presence of superoxide, which is a derivative of the 
mass muscular ischemia5.
After reperfusion muscle, is released into the circulation 
of acid metabolites and products of cell destruction that cause 
significant metabolic alterations, such as metabolic acidosis and 
hyperkalemia5. The more severe change is due to precipitation of 
myoglobin in the renal tubules in acid environment, causing acute 
tubular necrosis6.
Treatment of acute ischemia reperfusion is only the 
affected territory reperfusion of which may lead to ischemia and 
reperfusion syndrome.
Many times reperfusion cannot be performed immediately 
after the onset of ischemia, since there is a very variable period of 
time between the first symptoms of the disease and emergency 
medical care.
Cilostazol is an antiplatet drug and vasodilator with 
antimitogenics and cardiotonic actions intended to reduce the 
symptoms of peripheral vascular disease, intermittent claudication7 
and prevention of recurrent cerebral stroke8.
We hypothesize that cilostazol inhibits platelet 
aggregation and promoting vasodilation could decrease the 
deleterious effects of ischemia and reperfusion syndrome. If 
administered at the onset of ischemia could reduce acute ischemic 
events, and consequently reduce renal injury after reperfusion.
The objective of this study is to assess the effect of 
cilostazol in the kidney and skeletal striated muscle of Wistar rats 
submitted to acute ischemia and reperfusion of hind limbs, since 
no experimental models in animals studies on the effectiveness of 
cilostazol in acute ischemia and reperfusion have been reported.
Methods
Forty three male Wistar rats aged ten months and average 
weight of 300g were used.
This study was approved by the Ethics Committee 
for Animal Experimentation and Manipulation (CEMEA) on 
10.03.2008 and according to Federal Law No. 11.794, of October 
8, 2008, and Decree No. 6689 of July 15, 2009 which regulated 
Law 11,794.
The experiment was developed at the Center for 
Technological Research (NPT) of Mogi das Cruzes University in 
the period from July/2008 to October /2010. 
Surgical technique
The animals were anesthetized and placed an orogastric 
tube.
Laparotomy was performed in 4cm long. The abdominal 
aorta was ligated just below the renal artery with propylene 7.09.
Proceeded to divided into two randomly groups:
Group I (Cilostazol) - 21 animals, received by the tube 
solution of cilostazol (Cebralat®, Libbs) at a concentration of 1 
mg/ml in 10mg/kg.
Group II (Sham) - 22 animals: received 10ml/kg saline 
solution 0.9%.
The solutions were administered immediately after aortic 
ligature.
The effectiveness of aortic ligature was confirmed by 
the appearance of pallor, cyanosis and decreased temperature on 
their hind legs for thermometry. The absence of pulse and flow 
in the aorta below the ligature was confirmed by intraoperative 
Dopplermetry.
Ischemic time
After aortic ligature, started to measure ischemia time 
and proceeded to the closure of the laparotomy.
After four hours of ischemia relaparotomy was performed 
in order to remove the aortic ligature and then, closed.
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Reperfusion time
After removing aortic ligature, started to measure time 
of reperfusion.
Two animals were excluded from the previous steps of 
the experiment because they died before the final reperfusion time. 
Forty one animals underwent a second phase, remaining in the 
study.
Proceeded to the distribution of animals in four groups 
according to the time of reperfusion:
Group IA: 11 animals that received cilostazol with 
reperfusion time of two hours.
Group IIA: 11 animals receiving saline solution 0.9%, 
with time of two hours of reperfusion.
Group IB: nine animals receiving cilostazol with 
reperfusion time of six hours.
Group IIB: ten animals receiving saline solution 0.9%, 
with time of six hours of reperfusion.
Kidney and muscle harvesting and euthanasia
The animals were anesthetized, a left nephrectomy was 
performed, and the hind limb muscles harvested and proceded the 
euthanasia.
The kidney and muscles of the left hind limb were 
divided into two parts, fixed in peraformaldehyde 10%. One 
part was designed to histological analysis and the other for 
immunohistochemical study.
Histological and immunohistochemical analysis
The histological changes were examined in muscle: 
interstitial edema, inflammatory infiltrate, hypereosinophilia 
fiber, cariopicnose and necrosis (Figure 1). In kidney: presence of 
myoglobin cylinders, vacuolar degeneration of tubular cells and 
acute tubular necrosis (Figure 2)5.
FIGURE 1 - Photomicrograph of histological section renal (440x 
magnification).
FIGURE 2 - Photomicrograph of histological section muscle (440x 
magnification).
For histological analysis were examined 10 microscopic 
fields non-coincident at 440x magnification of each sample.
The results of the histological analysis were expressed in 
a semi-quantitative percentage as the ratio of expression changes 
observed in the total:
0 = absent;
1 = less than 10%;
2 = 11% to 25%;
3 = 26% to 50%;
4 = more than 51%.
The presence of apoptosis was evaluated by 
immunohistochemical expression of cleaved caspase 3 and 
TUNEL (TdT mediated dUTP nick endlabeling).
A sample of each animal resulted in two slide sections for 
the immunohistochemical analysis.
To determine the levels of immunohistochemical 
expression we used the technique of counting poins. We used a 
microscope equipped with an eyepiece and a grid of 50 rows and 
100 points by 440x magnification. We examined 10 non-coincident 
microscopic fields on each piece to quantify all the points that 
fell on the stained portions, totaling 1000 points covering an area 
of 62.500 µm2 per field of study. Points falling on stained areas 
represent the proportion of positively stained cells in the tissue 
area10 (Figure 3).
FIGURE 3 – Photomicrograph of the technique for measuring the 
expression of cleaved caspase-3 in kidney reticulum (440x magnification).
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The results of histological analysis and expression of 
immunohistochemical markers were tested using non-parametric 
Mann-Whitney (Wilcoxon Rank-Sum Test) for two independent 
samples, p ≤0.05 for significance. It was also made a graph of the 
95% confidence interval of the mean for immunohistochemistry 
between groups with six hours of reperfusion.
Results
Histological evaluation
Histological changes observed in muscle and kidney 
that received cilostazol compared to control group showed no 
significant differences in two and six hours of reperfusion.
Immunohistochemical evaluation
The expression of cleaved caspase 3 in the kidney and 
TUNEL expression in the kidney and muscle are shown in Table 
1 (next page).
The results showed that the total number of cells 
undergoing apoptosis quantified by cleaved caspase 3 and TUNEL 
was lower in the kidneys of animals that received cilostazol with 
six hours of reperfusion, however these differences were not 
statistically significant (Figures 4 and 5).
FIGURE 4 – Chart of 95% confidence interval of the average of groups 
of six hours of reperfusion: caspase-3 cleaved in the kidney.
FIGURE 5 - Chart of 95% confidence interval of the average of groups 
of six hours of reperfusion: TUNEL in the kidney.
Discussion
The Cilostazol has been widely used in the treatment of 
chronic peripheral arterial disease and in treatment of ischemic 
coronary artery disease due to its antiplatelet and vasodilatation 
properties7.
The therapeutic use of cilostazol in acute ischemia 
and its role in prevention of reperfusion syndrome has not been 
recommended. The lack of randomized controlled studies, using 
cilostazol in ischemia and reperfusion in rat kidney and muscle, 
we have motivated the design of this research. In this study it 
was hypothesized that cilostazol might have efficacy in treating 
acute ischemia and would decrease the metabolic syndrome of 
reperfusion protects target organs such as muscle and kidney.
Experimental studies have demonstrated that cilostazol 
obtained a protective effect against ischemic injury in animal 
models when used in another organs than skeletal muscle and 
kidneys11-13. 
Several experimental studies had model and design 
similar to our study to investigate the effectiveness of other drugs 
in ischemia and reperfusion6,15,16.
A recent experimental study demonstrated that cilostazol 
reduces the oxidative stress of ischemia and reperfusion in rats 
subjected to 45 minutes of spinal cord ischemia by clamping 
the aorta and a reperfusion period of 48 hours. The biochemical 
and histopathological analysis of the treated animals at a dose 
of cilostazol 20 mg/kg orally for three days before spinal cord 
ischemia, demonstrated a reduction in neurological damage and a 
reduction of oxidative stress16.
The tissue injury caused by ischemia and reperfusion is 
described as early onset, and studies have shown that histological 
changes are observable by microscopy after four hours of ischemia 
and 15 minutes of reperfusion14.
In this study, histological changes due to ischemia and 
reperfusion were observed in the kidney and striated muscle in 
similar intensity in the animals receiving cilostazol and those who 
received only saline solution. These changes were independent of 
reperfusion time, since it did not differ significantly in the two 
groups and underwent six hours of reperfusion.
The expression of cleaved caspase 318 and TUNEL19 for 
quantification of apoptosis currently have been used.
The expression of cleaved caspase 3 and TUNEL was 
lower in the cilostazol group with six hours of reperfusion, but 
not statistically significant. Therefore these results suggest that 
cilostazol could have a positive effect to reduce renal apoptosis in 
later periods of reperfusion.
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Another hypothesis could be due to the number of 
subjects used, which the analysis of a few animals per group, had 
no power to find statistically significant differences.
 
Conclusion
Cilostazol had no protective effect on the kidney and the 
skeletal striated muscle in rats submitted to acute ischemia and 
reperfusion in this model.
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